Pulmonary Embolism Clinical Trial
Official title:
The Acute Pulmonary Embolism 1 (APE 1) Trial: Prospective Investigation of Scintigraphic Diagnosis and Pathophysiology of Right Heart Strain
The purpose of this study is to
- investigate which method and criterion for diagnosing pulmonary embolism is the best
and
- determine the relationship between blood vessel constriction and clot size in patients
developing heart failure
INTRODUCTION This project assesses both scintigraphic diagnosis and the pathophysiology of
right heart strain in acute pulmonary embolism. The primary purposes are to validate various
scintigraphic methods with pulmonary angiography as the standard of reference (purpose A).
Furthermore, this project examines the relative contributions of 1) vascular obstruction, 2)
vasoactive mediators, and 3) co-morbidity to the generation of right heart strain (purpose
B).
BACKGROUND FOR PURPOSE A Acute pulmonary embolism is a life threatening condition. Early
intervention can be lifesaving but treatment is associated with severe side effects. Thus,
establishing accurate diagnosis is necessary. Clinical presentation and physical examination
have proven insufficient for this purpose. This is also true for basic diagnostic
investigations, e.g. electrocardiography, arterial blood gas analysis and chest x-ray, which
are considered standard tests in patients with symptoms consistent with cardiopulmonary
disease.
For several decades lung scintigraphy has been considered a cornerstone in the diagnosis of
acute pulmonary embolism. Planar two-dimensional images of the pulmonary perfusion are
obtained using a gamma camera after intravenous injection of radiolabelled microparticles,
depicting perfusion defects caused by e.g. a pulmonary embolus. Similarly, ventilatory
function can be assessed two-dimensionally by planar scintigraphic imaging following
inhalation of a radioactive gas or aerosol. Lung scintigraphy has certain limitations,
primarily related to image interpretation. The PIOPED criteria, based on the combined
ventilation-perfusion scintigraphy, have gained global acceptance, but are often
inconclusive and give rise to misunderstandings. A different set of interpretation criteria,
provided by the PISA-PED study group, are based solely on perfusion imaging. Opposite the
PIOPED criteria, PISA-PED criteria are always conclusive and exhibits both high sensitivity
and specificity. The latter have, however, not gained the same widespread acceptance as the
PIOPED criteria. It remains uncertain which set of criteria is the better to confirm or
exclude the diagnosis of acute pulmonary. A prospective trial evaluating both PIOPED
criteria (original and revised) and PISA-PED criteria against a valid standard of reference
therefore seems appropriate.
The more resource demanding single photon emission computed tomography (SPECT) has recently
been subject to renewed interest in the diagnosis of acute pulmonary embolism, but it
remains unclear whether this technique offers additional information compared to
conventional planar imaging. SPECT offers three-dimensional images, but otherwise the
technique is similar to the methods described for planar images. Combining the PISA-PED
criteria and SPECT imaging has not yet been tested in a prospective trial, but it seems
highly relevant.
Since the diagnosis is often suspected several times in the same patient, the ability to
distinguish acute and chronic changes in the scintigrams are essential. It is, however,
unclear to what extend and how fast the scintigraphic changes resolve. This has great
implications in scintigraphic control of patients recovering from acute pulmonary embolism.
A trial regarding the statements above requires a reliable method to test whether the
patient is suffering from acute pulmonary embolism or not: a standard of reference.
Pulmonary angiography is traditionally conceived as the standard of reference in acute
pulmonary embolism, but only a few newer studies employ this technique.
BACKGROUND FOR PURPOSE B Right heart strain is a common finding in acute pulmonary embolism.
It is a result of the sudden increase in pressure in the pulmonary circulation.
Ultrasonographic examination of the heart by echocardiography is suitable to demonstrate
this condition and this finding in a patient with acute pulmonary embolism is associated
with a considerably worse prognosis. The degree of right heart strain is not exclusively
determined by extension or size of the embolus. There is substantial evidence of the
influence of both co-morbidity and the release of vasoactive mediators on the extend of
right heart strain. The exact interplay between these three factors is not completely
understood in humans. Albeit, this can have significant implications on therapy, since
pharmacological manipulation of vascular tone in the pulmonary circulation is possible. This
treatment is, however, not without risk, and no well-designed study has yet addressed these
issues in patients with acute pulmonary embolism. Several case reports on successful
treatment with vasodilation, e.g. with inhaled nitric oxide, have been published. A more
profound understanding of the etiology of acute right heart failure in acute pulmonary
embolism is therefore desirable. What is the individual contribution of 1) clot burden, 2)
release of vasoactive mediators, and 3) co-morbidity?
Recently, acute pulmonary embolism has been divided into three categories depending on
clinical presentation and echocardiographic findings: 1) massive; in which the patient
suffers from cardiac arrest or cardiogenic shock. Most authorities agree that these patients
should be treated with fibrinolytic agents. 2) Non-massive; with no signs of shock or right
heart strain. In these patients there is no indication for fibrinolytic agents. 3)
Sub-massive; with no manifestations of shock but echocardiographic findings consistent with
right heart strain. The indication for fibrinolytic treatment in this last group is
unresolved. This study will address whether simple methods, e.g. peripheral blood sampling
and perfusion scintigraphy can determine the primary mechanism in the generation of right
heart strain in the individual patient.
A later (not yet planned) intervention study based on the abovementioned knowledge could
then address the following question: Should the patient with sub-massive pulmonary embolism
receive treatment with fibrinolytic agents (in the case of major clot burden and minor
degree of pulmonary vasoconstriction) or vasodilators (minor clot burden, major degree of
pulmonary vasoconstriction)?
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |